- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04169360
Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder (SEARCH)
25 januari 2021 bijgewerkt door: Sarah Kattakuzhy, University of Maryland, Baltimore
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy.
Patients will be randomized to two arms: (1) ANS-6637 for three months vs (2) Placebo for three months.
Subjects will subsequently be followed for an additional one month post treatment.
Studie Overzicht
Toestand
Ingetrokken
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy.
At screening, after providing consent, participants will be evaluated to ensure criteria for opioid use disorder by DSM V criteria is met, and whether the subject is receiving opioid agonist therapy will be determined.
Participants will undergo a medical evaluation (including medical history, laboratory tests and EKG evaluation) to establish baseline medical and psychiatric diagnosis in order to ensure safety of participation.
Once enrollment criteria are met, patients will be randomized in a blinded fashion to ANS-6637 or placebo, stratified by site and form of opioid agonist therapy.
On Day 0, patients will be initiated on ANS-6637 vs. placebo according to randomization group.
Subjects will be seen twice per week for two weeks, followed by weekly for two weeks, and then monthly for two months.
Studietype
Ingrijpend
Fase
- Fase 2
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 65 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Must have the ability to understand and must personally sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- Must be between 18 and 65 years of age, inclusive.
- Must have the diagnosis of opioid use disorder by DSM (Diagnostic and Statistical Manual of Mental Disorders) V criteria of at least mild severity
- Must have a total score of 9 or greater (out of a total of 30) on the Opioid Craving Scale at screening
- If on opioid agonist therapy, must be on Opioid Agonist Therapy (OAT) medication for a minimum of six months prior to screening.
- If on medication for depression or anxiety, must be on a stable dose for a minimum of two months prior to screening.
- Must be able to take oral medication and be willing to adhere to the medication regimen
- Must agree to utilize the "AI Cure" platform, either on their personal phone or on a supplied device, for both daily video adherence monitoring as well as daily questionnaires for the entire study duration.
- Male subjects must refrain from sperm donation throughout the study period, and continuing for at least 90 days following the last dose of study drug.
- Subjects must refrain from blood donation throughout the study period, and continuing for at least 30 days following the last dose of study drug.
- Must be willing to comply with contraception guidelines: The fetal risks associated with ANS-6637 are not known, but pre-clinical animal data demonstrate some risk. Subjects must agree not to become pregnant or impregnate a female. Females of childbearing potential must have a pregnancy test at screening and baseline (Day 0). If pregnancy occurs or is suspected to occur, study staff must be notified immediately. For the duration of the study, subjects or female partners of childbearing potential must use one of the following, unless she is surgically sterile, post-menopausal, or partner is surgically sterile: oral contraceptives (OCP), contraceptive sponge, patch double barrier (diaphragm + spermicide or condom + spermicide), intrauterine device (IUD), etonogestrel implant, injection, hormonal vaginal contraceptive ring or complete abstinence
- Must be willing and able to comply with all study requirements and plan to attend all clinic visits.
Exclusion Criteria:
A subject will be ineligible for this study if 1 or more of the following criteria are met:
- Clinically significant AND grade 2 or higher abnormal laboratory values at screening, as determined by principal investigator
- Aspartate transaminase (AST) or Alanine transaminase (ALT) > 2.5 x upper limit of normal or total bilirubin > 1.6 x the upper limit of normal
- Creatinine clearance < 60 mL/min/1.73m2 by Chronic kidney disease (CKD)-Epidemiology Collaboration (EPI) Score.
- Personal or family history of Parkinson's Disease
- Diagnosed major depression AND with current self-reported depression episode
- Diagnosed generalized anxiety disorder AND with current self-reported uncontrolled anxiety
- Current self-reported suicidal ideation
- Diagnosed liver disease, including untreated chronic Hepatitis C (defined as detectable Hepatitis C RNA), Hepatitis B (defined as positive HBsAg), and/or cirrhosis (defined as Fibrosis (FIB)-4 > 3.25 AND confirmed by Fibroscan or Fibrosure)
- Diagnosed Human Immunodeficiency Virus (HIV) AND detectable viral load > 40 copies/mL
- Diagnosed moderate or serious dementia Taking any of the following medications in the last 6 months: dopamine agonist, dopamine antagonist, anti-psychotic, anti-convulsant (except for benzodiazepines and gabapentin) or barbiturate
- Inability to obtain venous access for sample collection.
- Had a prior history of any severe adverse reactions to ethanol [e.g., flushing (noticeable redness of the neck or throat) and/or increased heart rate (subject reports sensation of increased heart rate or palpitations) after drinking alcohol].
- Known hypersensitivity to formulation excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc.
- Have previously participated in an investigational trial involving administration of any investigational compound within 30 days prior to screening
- Have any unresolved legal issues that could jeopardize continuation or completion of the study, at the discretion of the principal investigator
- Have any serious or active medical, surgical, or psychiatric conditions which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
- Are unable to comply with study requirements
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: ANS-6637
ANS-6637 600mg once daily for 12 weeks
|
White, oblong 300 mg tablet
|
|
Placebo-vergelijker: Placebo arm
Placebo 600 mg once daily for 12 weeks
|
White, oblong 300 mg tablet
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Grade 3-4 events, Grade 2 Significant event
Tijdsspanne: 16 weeks
|
The number of Grade 3-4 adverse events, as defined by the Division of AIDS (DAIDS) Toxicity Table Version 2.1, July, 2017 as well as the number of Grade 2 events requiring medication interruption or deemed clinically significant by a study investigator
|
16 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Urine Drug Screen
Tijdsspanne: 16 weeks
|
Percentage opioid free period by urine drug screen
|
16 weeks
|
|
Opioid Craving
Tijdsspanne: 16 weeks
|
Opioid craving will be assessed using the Opioid Craving scale questionnaire.
The questionnaire consists of three questions and each of these questions has a minimum value of 0 and a maximum value 10.
A score of 0 on each question is the best outcome; a score of 10 on each question is the worst outcome.
|
16 weeks
|
|
Opioid Agonist Therapy (OAT) concentration
Tijdsspanne: 16 weeks
|
Serum concentration of buprenorphine or methadone
|
16 weeks
|
|
Self reported description of drug use (Self-reported frequency/quantity/mode of opioid use, self-reported use of other drugs, overdose and overdose death)
Tijdsspanne: 16 weeks
|
Self-reported frequency/quantity/mode of opioid use as well as self-reported use of other drugs will be gathered using the Drug Use Survey.
Subjects will indicate frequency of opioid use by documenting the number of times they used an opioid during a given day.
The quantity of opioids used will be determined by the dollar amount of opioids the subject reports they have consumed during that day.
Subjects will also report mode of opioid use by indicating whether they are using opioids via injection, skin popping, snorting or oral.
The Drug Use Survey will also ask subjects to report incidence of use of non-opioid substances.
Incidence of overdose will be captured with the Naloxone questionnaire which asks, "since you last visit, have you experienced an overdose?".
Incidence of overdose death will measured by the number of medical examiner confirmed deaths of study participants with cause of death listed as "overdose related to an opioid".
|
16 weeks
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Darke HIV Risk Taking Behavior Survey Score
Tijdsspanne: 16 weeks
|
The Darke HIV Risk Taking Behavior Questionnaire will be administered to assess subject's self-reported risk taking behaviors.
Total scores on the test range from 0 to 55, with higher scores indicating a greater degree of risk-taking behavior.
|
16 weeks
|
|
Change in HIV Test Result
Tijdsspanne: 16 weeks
|
An HIV test (fourth generation antigen/antibody test) will be administered and the results are reported as either positive or negative.
|
16 weeks
|
|
Change in Hepatitis C (HCV) RNA result
Tijdsspanne: 16 weeks
|
A Hepatitis C (HCV) RNA test will be administered.
This test measures the quantity of detectable RNA which is measured in IU/ml.
|
16 weeks
|
|
Change in appetite
Tijdsspanne: 16 weeks
|
Self reported changes in appetite will be captured by the Adverse Event Survey.
The survey will ask, "since your last visit, have you had an increase in your appetite or a decrease in your appetite?".
|
16 weeks
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Sarah Kattakuzhy, MD, Institute of Human Virology at the University of Maryland
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Verwacht)
1 januari 2021
Primaire voltooiing (Werkelijk)
12 januari 2021
Studie voltooiing (Werkelijk)
12 januari 2021
Studieregistratiedata
Eerst ingediend
5 november 2019
Eerst ingediend dat voldeed aan de QC-criteria
16 november 2019
Eerst geplaatst (Werkelijk)
19 november 2019
Updates van studierecords
Laatste update geplaatst (Werkelijk)
28 januari 2021
Laatste update ingediend die voldeed aan QC-criteria
25 januari 2021
Laatst geverifieerd
1 januari 2021
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HP-00088649
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
The investigator will share de-identified data with approved outside collaborators under appropriate agreements, at the time of publication or shortly thereafter.
IPD-tijdsbestek voor delen
Data will be available at the time of publication or shortly thereafter, and will be kept indefinitely.
IPD-toegangscriteria voor delen
Will be determined by Principal Investigator
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ANALYTIC_CODE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Ja
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .